Skip to main content
Erschienen in: Rheumatology International 2/2016

01.02.2016 | Original Article - Epidemiology of RMD

Liver cirrhosis in selected autoimmune diseases: a nationwide cohort study in Taiwan

verfasst von: Chien-Hsueh Tung, Ning-Seng Lai, Ming-Chi Lu, Ching-Chih Lee

Erschienen in: Rheumatology International | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

The association between autoimmune diseases and liver cirrhosis has rarely been explored in Asian populations, an endemic area of viral hepatitis. The aim of this study was to investigate the comparative risk of liver cirrhosis among a group of selective autoimmune diseases in Taiwanese patients and to identify groups of high risk. This retrospective study was a nationwide, population-based study and used Taiwan’s National Health Insurance Research Database. A total of 29,856 patients with definite diagnosis of selected autoimmune diseases (Registry of Taiwan Catastrophic Illness Database, ACR classification) at the starting time point of January 1, 2005, were enrolled in this study. After tracked for a 5-year period, the endpoints were diagnosis of liver cirrhosis (in accordance with International Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9-CM codes 571). The control group was composed of other patients in the same database and consisted of randomly selected 753,495 sex- and age-matched non-autoimmune disease patients. The Cox proportional hazard regression model was used to calculate the risk of liver cirrhosis after adjusting for certain variables such as comorbidity, living area, and socioeconomic status. Among the patients with selected autoimmune diseases, 1987 liver cirrhosis were observed. Patients with psoriasis had a significantly increased risk of liver cirrhosis (HR 1.87, 95 % CI 1.25–2.81) than control group without psoriasis. The risk of liver cirrhosis was significantly lower in patients with rheumatoid arthritis (HR 0.29, 95 % CI 0.19–0.44). There is a gradient of risk of liver cirrhosis among the autoimmune diseases; the specific risks need to be investigated on the basis of hypotheses. Conventional immunosuppressive drug administration should be carefully implemented by regular monitoring of liver condition in order to avoid causing an adverse effect of chronic liver fibrosis.
Literatur
2.
Zurück zum Zitat Vassilopoulos D, Calabrese LH (2012) Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol 8:348–357CrossRefPubMed Vassilopoulos D, Calabrese LH (2012) Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol 8:348–357CrossRefPubMed
3.
Zurück zum Zitat Richard S, Guerret S, Gerard F, Tebib JG, Vignon E (2000) Hepatic fibrosis in rheumatoid arthritis patients treated with methotrexate: application of a new semi-quantitative scoring system. Rheumatology 39:50–54CrossRefPubMed Richard S, Guerret S, Gerard F, Tebib JG, Vignon E (2000) Hepatic fibrosis in rheumatoid arthritis patients treated with methotrexate: application of a new semi-quantitative scoring system. Rheumatology 39:50–54CrossRefPubMed
4.
Zurück zum Zitat Lindsay K, Fraser AD, Layton A, Goodfield M, Gruss H, Gough A (2009) Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology 48:569–572CrossRefPubMed Lindsay K, Fraser AD, Layton A, Goodfield M, Gruss H, Gough A (2009) Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology 48:569–572CrossRefPubMed
5.
Zurück zum Zitat Paredes MM, Chirinos MNJ, Martinez AA, Lozano A (2014) The most common rheumatic diseases in patients with autoimmune liver disease in the Hospital Arzobispo Loayza from 2008–2013, Lima, Peru. Rev Gastroenterol Peru 34:305–310 Paredes MM, Chirinos MNJ, Martinez AA, Lozano A (2014) The most common rheumatic diseases in patients with autoimmune liver disease in the Hospital Arzobispo Loayza from 2008–2013, Lima, Peru. Rev Gastroenterol Peru 34:305–310
6.
Zurück zum Zitat De Santis M, Crotti C, Selmi C (2013) Liver abnormalities in connective tissue diseases. Best Pract Res Clin Gastroenterol 27:543–551CrossRefPubMed De Santis M, Crotti C, Selmi C (2013) Liver abnormalities in connective tissue diseases. Best Pract Res Clin Gastroenterol 27:543–551CrossRefPubMed
7.
Zurück zum Zitat Schwingel PA, Cotrim HP, Salles BR, Almeida CE, dos Santos CR Jr, Nachef B, Andrade AR, Zoppi CC (2011) Anabolic-androgenic steroids: a possible new risk factor of toxicant-associated fatty liver disease. Liver Int 31:348–353CrossRefPubMed Schwingel PA, Cotrim HP, Salles BR, Almeida CE, dos Santos CR Jr, Nachef B, Andrade AR, Zoppi CC (2011) Anabolic-androgenic steroids: a possible new risk factor of toxicant-associated fatty liver disease. Liver Int 31:348–353CrossRefPubMed
8.
Zurück zum Zitat Park SH, Choe JY, Kim SK (2010) Assessment of liver fibrosis by transient elastography in rheumatoid arthritis patients treated with methotrexate. Joint Bone Spine 77:588–592CrossRefPubMed Park SH, Choe JY, Kim SK (2010) Assessment of liver fibrosis by transient elastography in rheumatoid arthritis patients treated with methotrexate. Joint Bone Spine 77:588–592CrossRefPubMed
9.
Zurück zum Zitat Bray AP, Barnova I, Przemioslo R, Kennedy CT (2012) Liver fibrosis screening for patients with psoriasis taking methotrexate: a cross-sectional study comparing transient elastography and liver biopsy. Br J Dermatol 166:1125–1127CrossRefPubMed Bray AP, Barnova I, Przemioslo R, Kennedy CT (2012) Liver fibrosis screening for patients with psoriasis taking methotrexate: a cross-sectional study comparing transient elastography and liver biopsy. Br J Dermatol 166:1125–1127CrossRefPubMed
10.
Zurück zum Zitat Boffa MJ, Smith A, Chalmers RJ (2009) Comment on: liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology 48:1464CrossRefPubMed Boffa MJ, Smith A, Chalmers RJ (2009) Comment on: liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology 48:1464CrossRefPubMed
12.
Zurück zum Zitat Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, Hasnian SS, Leung N, Lesmana L, Phiet PH, Sjalfoellah Noer HM, Sollano J, Sun HS, Xu DZ (2000) Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 15:1356–1361CrossRefPubMed Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, Hasnian SS, Leung N, Lesmana L, Phiet PH, Sjalfoellah Noer HM, Sollano J, Sun HS, Xu DZ (2000) Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 15:1356–1361CrossRefPubMed
13.
Zurück zum Zitat Chen DS (1995) Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Princess Takamatsu Symp 25:27–32PubMed Chen DS (1995) Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Princess Takamatsu Symp 25:27–32PubMed
14.
Zurück zum Zitat Tsai JF, Chang WY, Jeng JE, Ho MS, Wang LY, Hsieh MY, Chen SC, Chuang WL, Lin ZY, Tsai JH (1993) Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan. J Med Virol 41:296–300CrossRefPubMed Tsai JF, Chang WY, Jeng JE, Ho MS, Wang LY, Hsieh MY, Chen SC, Chuang WL, Lin ZY, Tsai JH (1993) Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan. J Med Virol 41:296–300CrossRefPubMed
15.
Zurück zum Zitat Watanabe R, Ishii T, Kobayashi H, Asahina I, Takemori H, Izumiyama T, Oguchi Y, Urata Y, Nishimaki T, Chiba K, Komatsuda A, Chiba N, Miyata M, Takagi M, Kawamura O, Kanno T, Hirabayashi Y, Konta T, Ninomiya Y, Abe Y, Murata Y, Saito Y, Ohira H, Harigae H, Sasaki T (2014) Prevalence of hepatitis B virus infection in patients with rheumatic diseases in Tohoku area: a retrospective multicenter survey. Tohoku J Exp Med 233:129–133CrossRefPubMed Watanabe R, Ishii T, Kobayashi H, Asahina I, Takemori H, Izumiyama T, Oguchi Y, Urata Y, Nishimaki T, Chiba K, Komatsuda A, Chiba N, Miyata M, Takagi M, Kawamura O, Kanno T, Hirabayashi Y, Konta T, Ninomiya Y, Abe Y, Murata Y, Saito Y, Ohira H, Harigae H, Sasaki T (2014) Prevalence of hepatitis B virus infection in patients with rheumatic diseases in Tohoku area: a retrospective multicenter survey. Tohoku J Exp Med 233:129–133CrossRefPubMed
16.
Zurück zum Zitat Maillefert JF, Muller G, Falgarone G, Bour JB, Ratovohery D, Dougados M, Tavernier C, Breban M (2002) Prevalence of hepatitis C virus infection in patients with rheumatoid arthritis. Ann Rheum Dis 61:635–637PubMedCentralCrossRefPubMed Maillefert JF, Muller G, Falgarone G, Bour JB, Ratovohery D, Dougados M, Tavernier C, Breban M (2002) Prevalence of hepatitis C virus infection in patients with rheumatoid arthritis. Ann Rheum Dis 61:635–637PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Taylor WJ, Korendowych E, Nash P, Helliwell PS, Choy E, Krueger GG, Soriano ER, McHugh NJ, Rosen CF (2008) Drug use and toxicity in psoriatic disease: focus on methotrexate. J Rheumatol 35:1454–1457PubMed Taylor WJ, Korendowych E, Nash P, Helliwell PS, Choy E, Krueger GG, Soriano ER, McHugh NJ, Rosen CF (2008) Drug use and toxicity in psoriatic disease: focus on methotrexate. J Rheumatol 35:1454–1457PubMed
18.
Zurück zum Zitat Thomas JA, Aithal GP (2005) Monitoring liver function during methotrexate therapy for psoriasis: Are routine biopsies really necessary? Am J Clin Dermatol 6:357–363CrossRefPubMed Thomas JA, Aithal GP (2005) Monitoring liver function during methotrexate therapy for psoriasis: Are routine biopsies really necessary? Am J Clin Dermatol 6:357–363CrossRefPubMed
19.
Zurück zum Zitat Wollina U, Stander K, Barta U (2001) Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis–short- and long-term toxicity in 104 patients. Clin Rheumatol 20:406–410CrossRefPubMed Wollina U, Stander K, Barta U (2001) Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis–short- and long-term toxicity in 104 patients. Clin Rheumatol 20:406–410CrossRefPubMed
20.
Zurück zum Zitat Salliot C, van der Heijde D (2009) Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68:1100–1104PubMedCentralCrossRefPubMed Salliot C, van der Heijde D (2009) Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68:1100–1104PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Kremer JM, Lee JK (1986) The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 29:822–831CrossRefPubMed Kremer JM, Lee JK (1986) The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 29:822–831CrossRefPubMed
22.
Zurück zum Zitat Ahern MJ, Smith MD, Roberts-Thomson PJ (1998) Methotrexate hepatotoxicity: What is the evidence? Inflamm Res 47:148–151CrossRefPubMed Ahern MJ, Smith MD, Roberts-Thomson PJ (1998) Methotrexate hepatotoxicity: What is the evidence? Inflamm Res 47:148–151CrossRefPubMed
23.
Zurück zum Zitat Laohapand C, Arromdee E, Tanwandee T (2015) Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients. Hepatol Int 9:202–208CrossRefPubMed Laohapand C, Arromdee E, Tanwandee T (2015) Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients. Hepatol Int 9:202–208CrossRefPubMed
24.
Zurück zum Zitat Tan J, Zhou J, Zhao P, Wei J (2012) Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol 31:1169–1175CrossRefPubMed Tan J, Zhou J, Zhao P, Wei J (2012) Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol 31:1169–1175CrossRefPubMed
25.
Zurück zum Zitat Lee YH, Bae SC, Song GG (2013) Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 31:118–121PubMed Lee YH, Bae SC, Song GG (2013) Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 31:118–121PubMed
26.
Zurück zum Zitat Amital H, Arnson Y, Chodick G, Shalev V (2009) Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate. Rheumatology 48:1107–1110CrossRefPubMed Amital H, Arnson Y, Chodick G, Shalev V (2009) Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate. Rheumatology 48:1107–1110CrossRefPubMed
27.
Zurück zum Zitat Lindsay K, Gough A (2008) Psoriatic arthritis, methotrexate and the liver—are rheumatologists putting their patients at risk? Rheumatology 47:939–941CrossRefPubMed Lindsay K, Gough A (2008) Psoriatic arthritis, methotrexate and the liver—are rheumatologists putting their patients at risk? Rheumatology 47:939–941CrossRefPubMed
28.
Zurück zum Zitat Kremer JM, Alarcon GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, Dent PB, Weinblatt ME (1994) Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 37:316–328CrossRefPubMed Kremer JM, Alarcon GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, Dent PB, Weinblatt ME (1994) Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 37:316–328CrossRefPubMed
Metadaten
Titel
Liver cirrhosis in selected autoimmune diseases: a nationwide cohort study in Taiwan
verfasst von
Chien-Hsueh Tung
Ning-Seng Lai
Ming-Chi Lu
Ching-Chih Lee
Publikationsdatum
01.02.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 2/2016
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-015-3369-z

Weitere Artikel der Ausgabe 2/2016

Rheumatology International 2/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.